Orbas-40 Tablet

About Orbas-40 Tablet

Orbas-40 40 mg is a tablet product of The ACME Laboratories Ltd. that contains Olmesartan Medoxomil. Lowering blood pressure helps reduce the strain on the heart and blood vessels.

There are 29 brands of Olmesartan Medoxomil listed in Bangladesh. The lowest listed price is Belsar 10 mg Tablet at ৳ 6.00 per unit.

What is Orbas-40 Tablet?

Orbas-40 40 mg is a tablet product of The ACME Laboratories Ltd. that contains Olmesartan Medoxomil. When this chemical is blocked, blood vessels relax and blood pressure can come down. By blocking this substance, Orbas-40 helps blood vessels relax and lowers blood pressure. The doctor decides the appropriate dose and course for each patient.

Uses of Orbas-40

Lowering blood pressure helps reduce the strain on the heart and blood vessels. It may be prescribed alone or in combination with other medicines that lower blood pressure. Orbas-40 is used to treat hypertension, which means high blood pressure. Your doctor will decide if this medicine is suitable for you and how it should fit into your overall treatment plan.

How to use Orbas-40

Food does not affect how the body absorbs Olmesartan. Orbas-40 is taken by mouth. Swallow the tablet with water. Keep the tablets in a dry place away from light and heat, and out of the reach of children. The dose and how often you take it will be decided by your doctor based on your condition. If you miss a dose, ask your doctor or pharmacist what to do.

Side effects of Orbas-40

Rare side effects include chest pain, swelling of the legs or arms, and arthritis. Commonly reported effects include back pain, bronchitis, diarrhea, headache, flu-like symptoms, and signs of inflammation in the nose or throat. Rarely, chest pain, swelling of the ankles or feet, and arthritis may occur. Tell your doctor if any side effect bothers you or does not go away. Tell your doctor if you experience any side effects.

Safety and precautions

Orbas-40 is not recommended during pregnancy, especially in the second and third trimesters, as medicines acting on the renin-angiotensin system can harm the developing fetus. Always consult your doctor or pharmacist if you have any concerns. Keep out of reach of children.

Frequently asked questions

What does Orbas-40 treat?

Lowering blood pressure helps reduce the strain on the heart and blood vessels. It may be prescribed alone or in combination with other medicines that lower blood pressure.

How is Orbas-40 used?

Food does not affect how the body absorbs Olmesartan. Orbas-40 is taken by mouth.

Can Orbas-40 cause side effects?

Rare side effects include chest pain, swelling of the legs or arms, and arthritis. Commonly reported effects include back pain, bronchitis, diarrhea, headache, flu-like symptoms, and signs of inflammation in the nose or throat.

Can I use Orbas-40 in pregnancy or while breastfeeding?

Orbas-40 is not recommended during pregnancy, especially in the second and third trimesters, as medicines acting on the renin-angiotensin system can harm the developing fetus. Always consult your doctor or pharmacist if you have any concerns.

Indications

Olmesartan Medoxomil is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Pharmacology

Angiotensin-II formed from angiotensin-I in a reaction catalyzed by angiotensin-converting enzyme (ACE), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin-II by selectively blocking the binding of angiotensin-II to the AT 1 receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland). In-vitro-binding studies indicate that Olmesartan is a reversible & competitive inhibitor of AT 1 receptor. Olmesartan does not inhibit ACE (kinase-I, the enzyme that converts angiotensin-I to angiotensin-II and degrades bradykinin).

Dosage & Administration

Dosage must be individualized. The usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have a greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.

No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance <40 ml/min) or with moderate to marked hepatic dysfunction. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function), Olmesartan should be initiated under close medical supervision and consideration should be given to use of a lower starting dose. Olmesartan may be administered with or without food.

Interaction

With medicine: No significant drug interactions were reported in which Olmesartan was co-administered.
With food & others: Food does not affect the bioavailability of Olmesartan.

Contraindications

Olmesartan is contraindicated in patients who are hypersensitive to any component of this product.

Side Effects

Common: The most common side effects include Back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, and sinusitis.

Rare: Chest pain, peripheral edema, arthritis.

Pregnancy & Lactation

Pregnancy: When pregnancy is detected, discontinue this product as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.

Nursing Mothers: It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Precautions & Warnings

As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with olmesartan medoxomil. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar results may be anticipated in patients treated with olmesartan medoxomil.

Overdose Effects

Symptoms: There is no experience of overdose with Olmesartan. The most likely effects of olmesartan medoxomil overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred.

Treatment: If intake is recent, gastric lavage or induction of emesis may be considered. Clinically significant hypotension due to an overdose of Olmesartan requires the active support of the cardiovascular system, including close monitoring of heart and lung function, the elevation of the extremities, and attention to circulating fluid volume and urine output.

Storage Conditions

Store in cool & dry place below 30ºC, protect from light & moisture. Keep out of the reach of children.

Alternative brands of Olmesartan Medoxomil

Other brands with the same generic name, cheapest first.

See all 29 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.